{"nctId":"NCT03987620","briefTitle":"Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis","startDateStruct":{"date":"2019-06-07","type":"ACTUAL"},"conditions":["Candida Vulvovaginitis"],"count":455,"armGroups":[{"label":"Ibrexafungerp (SCY-078)","type":"EXPERIMENTAL","interventionNames":["Drug: Ibrexafungerp"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Ibrexafungerp","otherNames":["SCY-078"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is a postmenarchal female subject 12 years and older\n* Subject has a diagnosis of symptomatic AVVC at baseline including a positive microscopic examination with 10% Potassium Hydroxide (KOH) in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal pH (â‰¤4.5)\n\nExclusion Criteria:\n\n* Subject has any vaginal condition other than AVVC that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection)\n* Need for systemic and/or topical (vaginal) anti fungal treatment, including prescription or over-the-counter products during the study and treatment for vulvovaginal candidiasis (VVC) 28 days prior to randomization.\n* Subject has uncontrolled diabetes mellitus.\n* Subject has a vaginal sample with pH \\>4.5.\n* Subject has a history of or an active cervical/vaginal cancer.","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Cure (Complete Resolution of Signs and Symptoms)","description":"The percentage of subjects with clinical cure (complete resolution of signs and symptoms) at the test-of-cure (TOC) visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"37","spread":null}]},{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Mycological Eradication (Negative Culture for Growth of Yeast)","description":"The percentage of subjects with mycological eradication (negative culture for growth of Candida species) at the TOC visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"25","spread":null}]},{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Cure and Mycological Eradication (Responder Outcome)","description":"The percentage of subjects with clinical cure and mycological eradication (responder outcome) at the TOC visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"23","spread":null}]},{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Clinical Response at Follow-up","description":"The percentage of subjects with complete resolution of signs and symptoms at the Follow-up (FU) visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"44","spread":null}]},{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability of Ibrexafungerp","description":"Number of subjects with treatment related adverse events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"44","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":298},"commonTop":["Headache","Diarrhoea","Nausea"]}}}